Revel Degen
Nurse Practitioner · Luverne, MNNPI 1841822004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 515 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,767, 6.4 times the $432 reported in 2021. Among nurse practitioner clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $14.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$898
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$803
- Supernus Pharmaceuticals, Inc.$735
- Alkermes, Inc.$497
- plus $2K from 18 others
What the payments were for
- Food & beverage$7,29495%
- Education$4015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 121 | $1,422 |
| Teva Pharmaceuticals USA, Inc. | 49 | $1,070 |
| Otsuka America Pharmaceutical, Inc. | 61 | $898 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $803 |
| Supernus Pharmaceuticals, Inc. | 57 | $735 |
| Alkermes, Inc. | 35 | $497 |
| Neurocrine Biosciences, Inc. | 33 | $473 |
| Johnson & Johnson | 15 | $304 |
| E.r. Squibb & Sons, L.L.C. | 17 | $199 |
| Vanda Pharmaceuticals Inc. | 10 | $191 |
| Lundbeck LLC | 10 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $170 |
| Idorsia Pharmaceuticals US Inc | 8 | $149 |
| Tris Pharma Inc | 5 | $91 |
| Axsome Therapeutics, Inc. | 5 | $89 |
| Noven Therapeutics, LLC | 5 | $88 |
| Corium, LLC | 12 | $86 |
| Avanir Pharmaceuticals, Inc. | 1 | $57 |
| Sunovion Pharmaceuticals Inc. | 3 | $55 |
| Sage Therapeutics, LLC | 3 | $49 |
| Almatica Pharma LLC | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Eisai Inc. | 1 | $13 |
How this compares
$7,695 in reported general payments places this provider in the 95th percentile of 3,021 nurse practitioner providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 26 | $36,628 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $19,187 |
| FetzimaLevomilnacipran Hcl | 13 | $6,323 |
| Paliperidone ErPaliperidone | 40 | $3,327 |
| Lisdexamfetamine Dimesylate | 13 | $3,122 |
| Carbamazepine ErCarbamazepine | 14 | $2,560 |
| Aripiprazole | 100 | $1,744 |
| Vilazodone Hcl | 13 | $1,543 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $1,415 |
| Olanzapine | 63 | $1,278 |
| Dexmethylphenidate Hcl ErDexmethylphenidate Hcl | 13 | $1,213 |
| Clorazepate Dipotassium | 20 | $1,204 |
| Quetiapine Fumarate | 78 | $1,108 |
| Divalproex Sodium | 96 | $967 |
| Thioridazine Hcl | 11 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,422 | $42,95139 claims |
| Alkermes, Inc.Lybalvi | $497 | $19,18712 claims |
| Almatica Pharma LLCSertraline Hcl | $35 | $57561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,021 nurse practitioner providers in Minnesota.
Other nurse practitioner in Luverne
- Jill ToliverWoodbury$116K
- Rebecca SuessBurnsville$110K
- Kelly YoungBurnsville$105K
- Kimberly ThompsonRochester$62K
- Janet WilkinsonMora$57K
- Virginia ClementsonEden Prairie$42K
- Erin PetersonSt Louis Park$37K
- Karen TrutnauEdina$32K
- Margaret VolzMinneapolis$30K
- Joanne HynesCoon Rapids$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.